A Phase I, Non-randomized, Open-label, Repeat Oral Administration Study of ASP3026 in Patients With Solid Tumors

Trial Profile

A Phase I, Non-randomized, Open-label, Repeat Oral Administration Study of ASP3026 in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs ASP 3026 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Dec 2012 Planned number of patients changed from 54 to 69 as reported by ClinicalTrials.gov.
    • 29 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top